Treatment with sorafenib plus camrelizumab after splenectomy for primary splenic angiosarcoma with liver metastasis: A case report and literature review

BACKGROUND: Primary splenic angiosarcoma (PSA) is an extremely rare and aggressive mesenchymal malignancy with high metastatic potential and a poor prognosis. There are no established treatment guidelines for PSA, even for adjuvant therapy. This rare case may provide a reliable therapeutic regime fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Dan, Li, Tai-Ping, Xiong, Jian-Hui, Wang, Shu-Bo, Chen, Yao-Xu, Li, Jian-Feng, Xiao, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968800/
https://www.ncbi.nlm.nih.gov/pubmed/35434106
http://dx.doi.org/10.12998/wjcc.v10.i9.2818
Descripción
Sumario:BACKGROUND: Primary splenic angiosarcoma (PSA) is an extremely rare and aggressive mesenchymal malignancy with high metastatic potential and a poor prognosis. There are no established treatment guidelines for PSA, even for adjuvant therapy. This rare case may provide a reliable therapeutic regime for a better prognosis. CASE SUMMARY: A 49-year-old female who complained of right-upper quadrant abdominal pain was diagnosed as having PSA with splenic rupture and liver metastasis. After splenectomy and liver tumor resection, she received sorafenib and camrelizumab therapy. After 15 mo of follow-up, she is in good condition, without recurrence or any identified metastasis. CONCLUSION: Immunotherapy combined with targeted therapy could be a potential option for the adjuvant therapy of PSA.

Ejemplares similares